New COPD Inhaler Treatment Comparison Study
Part of Lungs & breathing clinical trials.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–75 years old
- Diagnosed with COPD at least 1 year before joining
- Current or former smoker with at least 10 pack-year smoking history (quit at least 6 months ago if former smoker)
- Healthy weight (BMI 18–30) and weigh at least 45 kg (about 99 lbs)
- Able to use inhalers correctly and perform breathing tests
- No asthma, recent lung infections, or serious heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe COPD. The goal is to see if it can help improve breathing and reduce flare-ups.
This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe chronic obstructive pulmonary disease (COPD). It aims to see if the drug can improve lung function and symptoms. For some participants, the trial is available to those who have not been in a previous TQC3721 study.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.